Bibliography
- Editorial. Genetic benefits at risk. Nature 2008;451:745-6
- Ito RK, Demers LM. Pharmacogenomics and pharmacogenetics: future role of molecular diagnostics in clinical diagnostic laboratory. Clin Chem 2004;50:1526-7
- University of Utah Research Foundation/Breast and Ovarian Cancer. Case no. T1213/05. Boards of Appeal of the European Patent Office. 27 September 2007
- Laboratory Corp. of America v. Metabolite Laboratories, Inc., 126 Sup. Ct. 2921; 2006
- Jensen K, Murray F. Intellectual property landscape of the human genome. Science 2005;301:239-40
- Holman CM. The impact of human gene patents on innovation and access: a survey of human gene patent litigation. Univ. Missouri Kansas City Law Rev (in press). Available from: http://ssrn.com/abstract=1090562 [Last accessed 19 April 2008]
- Nuffield Council on Bioethics. The Ethics of Patenting DNA: A Discussion Paper. Nuffield Council on Bioethics: London; 2002
- Goldstein JA, Golod E. Human gene patents. Acad Med 2002;77:1315
- Barton JH. Patents, genomics, research, and diagnostics. Acad Med 2002;77:1339-47
- Eisenberg RS. Genes, patents and product development. Science 1992;257:903-8
- Rai AK. Genome patents: a case study in patenting research tools. Acad Med 2002;77:1368-72
- Verbeure B, Matthijs G, Van Overwalle G. Analysing DNA patents in relation with diagnostic genetic testing. Eur J Hum Genetics 2005:1-8
- Paradise J, Andrews L, Holbrook T. Patents on human genes: an analysis of scope and claims. Science 2005;307:1566-7
- National Research Council Committee on Intellectual Property Rights in Genomic and Protein Research and Innovation. Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation and Public Health. National Academies Press, Washington: DC; 2006
- Hopkins MM, Mahdi S, Thomas SM, Patel P. The Patenting of Human DNA: Global Trends in Public and Private Sector Activity (the PATGEN Project). Science Technology Policy Research Unit, Brighton; 2006
- Williams-Jones B. History of a gene patent: tracing the development and application of commercial BRCA testing. Health Law J 2002;10:121-44
- Rimmer M. Myriad Genetics: patent law and genetic testing. Eur Int Prop Rev 2003;25:20-33
- Skolnick MH, Goldgar GE, Miki Y, et al. 170-Linked breast and ovarian cancer susceptibility gene. US5753441; 1998
- Gusella JF, Wexler NS, Conneally PM, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983;306:234-8
- Gusella JF. Test for Huntington's disease. US4666828; 1987
- Macdonald ME, Ambrose CM, Duyao MP, Gusella JF. Huntingtin DNA, protein and uses thereof. US5686288; 1997
- National Research Council. Intellectual property rights and research tools in molecular biology. Summary of a Workshop Held at the National Academy of Sciences. National Academies Press, Washington DC; 1996
- Cohen SN, Boyer HW. Process for producing biologically functional molecular chimeras. US4237224; 1980
- Cohen SN, Boyer HW. Biologically functional molecular chimeras. US4740470; 1988
- Mullis KB. Process for amplifying nucleic acid sequences. US4683202; 1987
- Mullis KB, Erlich HA, Arnheim N, et al. Process for amplifying, detecting, and/or 68 cloning nucleic acid sequences. US4800159; 1989
- Mullis KB, Erlich HA, Gelfand DH, et al. Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme. US4965188; 1990
- Simons MJ. Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes. US5192659; 1993
- Simons MJ. Genomic mapping method by direct haplotyping using intron sequence analysis. US5851762; 1998
- Simons MJ. Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes. US5612179; 1997
- Nicol D. On the legality of gene patents. Melbourne Univ Law Rev 2005;29:809-42
- Re Bell, 991 F2d 781 (Fed Cir, 1993)
- Re Deuel, 51 F3d 1552 (Fed Cir, 1995)
- United States Patent and Trademark Office. Utility examination guidelines. Fed Reg 2001;66:1092, 1095
- Re Fisher, 421 F3d 1365 (Fed Cir, 2005)
- Skolnick MH, Goldgar GE, Miki Y, et al. Method for diagnosing a predisposition for breast and ovarian cancer. EP699754; 1996
- Shattuck-Eidens DM, Simard J. In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene. EP705903; 1996
- Skolnick MH, Goldgar GE. 17q-Linked breast and ovarian cancer susceptibility gene. EP705902; 1996
- European Patent Office. ‘Myriad/breast cancer’ patent revoked after public hearing. Press release, 18 May 2004. Available from: http://www.epo.org/about-us/press/releases/archive/2004.html [Last accessed 3 March 2008]
- European Patent Office. Patent on breast and ovarian cancer susceptibility gene amended after public hearing. Press release, 21 January 2005. Available from: http://www.epo.org/about-us/press/releases/archive/2005.html [Last accessed 3 March 2008]
- European Patent Office. European patent on mutations in breast and ovarian cancer susceptibility gene amended after public hearing. Press release, 25 January 2005. Available from: http://www.epo.org/about-us/press/releases/archive/2005.html [Last accessed 3 March 2008]
- Vermij P. BRCA1 patent revisited. Nat Biotechnol 2005;23:277
- Convention on the Grant of European Patents. Opened for signature 5 October 1973. United Nations Treaty Series 1065:254 (Entered into force 7 October 1977)
- Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the Legal Protection of Biotechnological Inventions. Official Journal of the European Communities L213:13 (Entered into force 30 July 1998)
- Howard Florey/Relaxin, Case number V0008/94. Opposition Division of the European Patent Office; 8 December 1994. [1995] EPOR 541
- Allen RH, Stabler SP, Lindenbaum J. Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficiency. US4940658; 1990
- Klein RD, Mahoney MJ. Labcorp v. Metabolite Laboratories: the Supreme Court listens, but declines to speak. J Law Med Ethics 2008;36:141-9
- Laboratory Corp. of America v. Metabolite Laboratories, Inc., 126 Sup. Ct. 543; 2005
- Metabolite Laboratories, Inc. v. Laboratory Corp. of America, No. 99-Z-870 (District of Colorado, 21 November 2001)
- Metabolite Laboratories, Inc. v. Laboratory Corp. of America, 370 F3d 1354 (Fed Cir, 2004)
- Cho MK, Illangasekare S, Weaver MA, et al. Effect of patents and licenses on the provision of clinical genetic testing services. J Mol Diagnostics 2003;5:3-8
- Paradise J. European opposition to exclusive control over predictive breast cancer testing and the inherent implications for United States patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy. Food Drug Law J 2004;59:133-54
- Pressman L, Burgess R, Cook-Deegan RM, et al. The licensing of DNA patents by US academic institutions: an empirical study. Nat Biotechnol 2006;24:31-9
- Mikhail P. Hopkins v CellPro: an illustration that patenting and exclusive licensing of fundamental science is not always in the public interest. Harvard J Law Technol 2000;13:375-94
- Walsh JP, Arora A, Cohen WM. Effects of research tool patenting and licensing on biomedical innovation. In: Cohen WM, Merrill SA, editors, Patents in the knowledge-based economy. National Academies Press: Washington DC; 2003. p. 285-340
- Nicol D. Balancing innovation and access to healthcare through the patent system: an Australian perspective. Comm Genet 2005;8:228-34
- Genetic Technologies Ltd. Company announcements: licensing update. 15 January 2008. Available from: http://www.gtg.com.au/index.asp?menuid=060.070.130&artid=10722&function=NewsArticle [Last accessed 3 March 2008]
- Genetic Technologies Ltd. Issued licences. Available from: http://www.gtg.com.au/index.asp?menuid=060.070.190.020 [Last accessed 3 March 2008]
- Ozdemir V, Williams-Jones B, Glatt SJ, et al. Shifting emphasis from pharmacogenomics to theragnostics. Nat Biotechnol 2006;24:942-6
- Merz JF, Kriss DG, Leonard DG, Cho MK. Diagnostic testing fails the test. Nature 2002;415:577-9
- Nicol D, Nielsen J. Patents and Medical biotechnology: an empirical analysis of issues facing the Australian industry. Centre for Law and Genetics, Hobart; 2003
- Green A, Wee R, Henaghan B. Biotechnology patents and the New Zealand health and research sectors [abstract]. Alberta Civil Liberties Research Centre Conference, One Origin, One Race, One Earth. Calgary, 15 – 17 November 2007. Available from: http://www.aclrc.com/OneOrigin/index.htm [Last accessed 31 March 2008]
- Stern S, Murray FE. Do formal intellectual property rights hinder the free flow of scientific knowledge? An empirical test of the anti-commons hypothesis. NBER Working Paper No. W11465 2005. Available from: http://ssrn.com/abstract=755701 [Last accessed 31 March 2008]
- Walsh JP, Cho C, Cohen W. View from the bench: patents and material transfers. Science 2005;309:2002-3
- Walpole IR, Dawkins HJS, Sinden PD, O'Leary PC. Human gene patents: the possible impacts on genetic services healthcare. Med J Aust 2003;179:203-5
- Barton JH. Emerging patent issues in genomic diagnostics. Nat Biotechnol 2006;24:939-41
- Eisenberg RS. Why the gene patenting controversy persists. Acad Med 2002;77:1381-7
- National Research Council, Committee on Intellectual Property Rights in the Knowledge-Based Economy. A patent system for the 21st century. Merrill SA, Levin RC, Myers MB, editors. National Academies Press: Washington DC; 2004
- Australian Law Reform Commission. Genes and ingenuity: gene patenting and human health. Report 99. Australian Government, Canberra; 2004
- Canadian Biotechnology Advisory Council. Report on human genetic materials, intellectual property and the health sector. Government of Canada, Ottawa; 2006
- Rimmer M. The freedom to tinker: patent law and experimental use. Expert Opin Ther Patents 2005;15:167-200
- De Francesco L. Genetic profiteering. Nat Biotechnol 2006;24:888-90
- Romeo-Malanda S, Nicol D. Pharmacogenetic testing: legal considerations for consent, privacy, and disclosure. Personalized Med 2008;5:155-61
- Batchelder K, Miller P. A change in the market: investing in diagnostics. Nat Biotechnol 2006;24:922-6
- Baker M. New-wave diagnostics. Nat Biotechnol 2006;24:931-9
- Eisenberg RS. Genomic patents and product development incentives. In: Knoppers BM, Laberge C, Hirtle M, editors, Human DNA: law and policy. Kluwer Law International, The Hague; 1997:373-8
- Shapiro C. Navigating the patent thicket: cross licences, patent pools and standard-setting. In: Jaffe A, Lerner J, Stern S, editors, Innovation Policy and the Economy. MIT Press: Cambridge, MA: 2001;119-50
- Heller MA, Eisenberg RS. Can patents deter innovation? The anticommons in biomedical research. Science 1998;280:698-702
- Caulfield T, Cook-Deegan RM, Keiff FS, Walsh JP. Evidence and anecdotes: an analysis of human gene patenting controversies. Nat Biotechnol 2006;24:1091-4
- Intellectual Property Institute. Patents for genetic sequences: the competitiveness of current UK law and practice. Department of Trade and Industry, London; 2004
- Organization for Economic Co-Operation and Development. Genetic inventions, intellectual property rights and licensing practices: evidence and policies. OECD, Berlin; 2002
- Caulfield BA. Why we hate gene patents. IP Worldwide. 30 December 2002. Available from: http://www.law.com/jsp/article.jsp?id=1039054490790 [Last accessed 28 February 2008]
- Organization for Economic Co-Operation and Development: Guidelines for the Licensing of Genetic Inventions. OECD, Paris; 2006
- National Institutes of Health. Principles and guidelines for recipients of NIH research grants and contracts on obtaining and disseminating biomedical research resources: final notice. Fed Reg 1999;64:72090
- National Institutes of Health. Best practices for the licensing of genomic inventions: final notice. Fed Reg 2005;70:18413
- Clark J, Piccolo J, Stanton B, Tyson K. Patent pools: a solution to the problem of access in biotechnology patents? United States Patent and Trademark Office: Washington DC; 2000
- Ebersole TJ, Guthrie MN, Goldstein JA. Patent pools and standard setting in diagnostic genetics. Nat Biotechnol 2005;23:937-8
- Resnik DB. A biotechnology patent pool: an idea whose time has come? J Phil Sci Law 2003;3. Available from: http://www6.miami.edu/ethics/jpsl/archives/papers/biotechPatent.html [Last accessed 31 March 2008]
- Van Overwalle G, Van Zimmern E, Verbeure B, Matthijs G. Models for facilitating access to patents on genetic inventions. Nat Rev Genetics 2006;7:143-8
- Verbeure B, Van Zimmeren E, Matthijs G, Van Overwalle G. Patent pools and diagnostic testing. Trends Biotechnol 2006;24:115-20
- Krattiger A, Kowalski S, Eiss R, Taubman A. Intellectual property management strategies to accelerate the development and access of vaccines and diagnostics: case studies on pandemic influenza, malaria and SARS. Innov Strategy Today 2006;2:67-122
- Gaulé P. Towards patent pools in biotechnology? Innov Strategy Today 2006;2:123-34
- Graff G, Zilberman D. Towards an intellectual property clearinghouse for agricultural biotechnology. Intellectual Prop Strategy Today 2001;3:1-14
- Van Zimmeren E, Verbeure B, Van Overwalle G, Matthijs G. A clearing house for diagnostic testing: the solution to ensure access to and use of patented genetic inventions? Bull World Health Org 2006;84:352-9
- Hope J. Biobazaar: the open source revolution and biotechnology. Harvard University Press: Cambridge, MA; 2008
- Nicol D, Hope J. Cooperative strategies for facilitating use of patented inventions in biotechnology. Law Context 2006;24:85-112
- Aymé S, Matthijs G, Soni S; On Behalf of the Eshg Working Party on Human Genetics. Patenting and licensing in genetic testing: recommendations of the European Society of Human Genetics. Eur J Hum Genetics 2008;16:405-11